Neovolta (NEOV) reported a fourth-quarter 2026 loss of 24 cents per share, far exceeding the 7-cent loss Wall Street had anticipated, as revenue fell to approximately $13.5 million—down 99.3% from estimates and nearly half of Q4 2025 levels. The company’s GAAP net loss widened to $11.7 million, driven by higher credit provisions and inventory reserves, while adjusted EBITDA turned negative at $8.0 million. Over the past year, the stock has declined 42%, following a regular trading session drop of 5.65% to $3.17 before plunging 20.83% after hours to $2.51. The stock remains within its 52-week range of $1.36 to $7.13 but has underperformed over the past year, reflecting broader investor skepticism amid a strategic realignment from residential battery storage to a broader energy storage platform targeting commercial, industrial, and utility markets.
The company’s Q4 2026 revenue of $13.5 million—down from $4.8 million in the prior year—contrasted sharply with full-year 2026 guidance of $13.3 million, a 58% year-over-year increase. Despite this growth, the fiscal 2026 net loss widened to $21.5 million, or 55 cents per share, from $5.0 million in fiscal 2025. Cash reserves stood at $25.4 million, bolstered by $50 million in equity financing and a $20 million senior secured term loan facility, with potential for an additional $10 million pending terms.
Neovolta’s operational pivot has accelerated production at its 210,600-square-foot Pendergrass, Georgia, facility, targeting 8 gigawatt-hours (GWh) of annual battery energy storage system (BESS) capacity by 2028. The company has already secured materials for the first 10 units and signed a five-year agreement with SK On to supply 9 GWh of U.S.-manufactured lithium-iron-phosphate (LFP) cells from 2027 to 2031, with potential for additional 9 GWh under a broader framework. Early demand visibility includes a $200 million pipeline from Infinite Grid Capital, with $53 million secured in binding capacity reservations.
Commercial deliveries are expected to begin in February to April 2027, following certification work starting in November 2026. A second production line, focused on pouch LFP cells, is set to ramp in the second half of 2027. Despite the earnings shortfall, NeoVolta’s balance sheet remains robust, with a current ratio of 8.1 and a financial health score of 1.78 out of 5 from InvestingPro. Analysts and investors now watch closely as the company transitions into a high-growth phase, though the near-term earnings gap has weighed on share prices.
